Menu Search
Equities

Haleon PLC

HLN:NYQ

Haleon PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.61
  • Today's Change0.095 / 0.90%
  • Shares traded3.88m
  • 1 Year change+28.23%
  • Beta--
Data delayed at least 15 minutes, as of Sep 16 2024 18:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in GBX

The 3 analysts offering 12 month price targets for Haleon PLC - ADR have a median target of 11.51, with a high estimate of 11.67 and a low estimate of 9.96. The median estimate represents a 9.49% increase from the last price of 10.51.
High11.0%11.67
Med9.5%11.51
Low-5.2%9.96

Dividends

Historical dividend information is not available for Haleon PLC.
Div growth (TTM)--
More ▼

Earnings history & estimates in GBX

On Aug 01, 2024, Haleon PLC - ADR reported 2nd quarter 2024 earnings of 7.67 per share. This result exceeded the 7.00 expectation of the one analyst covering the company and exceeded last year's 2nd quarter results by 6.26%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+9.13%
Haleon PLC - ADR reported annual 2023 earnings of 34.60 per share on Feb 29, 2024.
More ▼

Revenue history & estimates in GBP

Haleon PLC - ADR had 2nd quarter 2024 revenues of 2.78bn. This missed the 2.79bn estimate of the one analyst following the company. This was 7.07% below the prior year's 2nd quarter results.
Average growth rate+0.28%
Haleon PLC - ADR had revenues for the full year 2023 of 11.30bn. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.